CME Group:UBS lowers PT to $285, maintains Neutral rating.
PorAinvest
lunes, 8 de septiembre de 2025, 8:34 am ET1 min de lectura
CME--
CME Group reported earnings per share (EPS) of $2.96 for the quarter, exceeding the consensus estimate of $2.91. The company also saw a year-over-year revenue increase of 10.4%. Additionally, several institutional investors, including GQG Partners and Wellington Management Group, significantly increased their stakes in the company during the first quarter. This increased ownership, coupled with the positive earnings report, has likely contributed to the upward trend in the stock's price.
However, UBS's lower price target suggests a cautious stance on the company's future prospects. The investment bank may be factoring in potential risks or market volatility that could impact CME Group's performance. Despite the lower price target, UBS maintains a Neutral rating, indicating a balanced view of the company's prospects.
Institutional ownership of CME Group remains notably high at 87.75%, with several investors significantly increasing their stakes. Amundi, for instance, sold 576,014 shares, reducing its position by 26.4%. Meanwhile, GQG Partners increased its stake by 7,676.3%, now owning 2,205,041 shares. Other notable increases include Wellington Management Group (370.5%) and GAMMA Investing LLC (32,941.0%).
CME Group has also seen a series of positive analyst ratings and price targets. Piper Sandler boosted its price objective to $296, while Barclays set a target of $298.00. Despite these positive developments, UBS's lower price target suggests a cautious approach to the company's future prospects.
References:
[1] https://www.marketbeat.com/instant-alerts/filing-amundi-sells-576014-shares-of-cme-group-inc-cme-2025-09-04/
[2] https://www.marketbeat.com/instant-alerts/filing-gotham-asset-management-llc-has-2393-million-stock-position-in-cme-group-inc-cme-2025-09-05/
UBS--
CME Group:UBS lowers PT to $285, maintains Neutral rating.
UBS has recently adjusted its price target for CME Group Inc. (NASDAQ:CME), lowering it to $285 from $305, while maintaining a Neutral rating. This move comes after a series of positive developments for the company, including a strong earnings report and increased institutional ownership.CME Group reported earnings per share (EPS) of $2.96 for the quarter, exceeding the consensus estimate of $2.91. The company also saw a year-over-year revenue increase of 10.4%. Additionally, several institutional investors, including GQG Partners and Wellington Management Group, significantly increased their stakes in the company during the first quarter. This increased ownership, coupled with the positive earnings report, has likely contributed to the upward trend in the stock's price.
However, UBS's lower price target suggests a cautious stance on the company's future prospects. The investment bank may be factoring in potential risks or market volatility that could impact CME Group's performance. Despite the lower price target, UBS maintains a Neutral rating, indicating a balanced view of the company's prospects.
Institutional ownership of CME Group remains notably high at 87.75%, with several investors significantly increasing their stakes. Amundi, for instance, sold 576,014 shares, reducing its position by 26.4%. Meanwhile, GQG Partners increased its stake by 7,676.3%, now owning 2,205,041 shares. Other notable increases include Wellington Management Group (370.5%) and GAMMA Investing LLC (32,941.0%).
CME Group has also seen a series of positive analyst ratings and price targets. Piper Sandler boosted its price objective to $296, while Barclays set a target of $298.00. Despite these positive developments, UBS's lower price target suggests a cautious approach to the company's future prospects.
References:
[1] https://www.marketbeat.com/instant-alerts/filing-amundi-sells-576014-shares-of-cme-group-inc-cme-2025-09-04/
[2] https://www.marketbeat.com/instant-alerts/filing-gotham-asset-management-llc-has-2393-million-stock-position-in-cme-group-inc-cme-2025-09-05/
Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema
Comentarios
Aún no hay comentarios